B
Bull
Bull · 25%CAH
$146.16
Szenariopreis
$234.620
+0.070 (+0.03%)Zum Schluss
Loading chart…
- High
- 236.970
- Open
- 234.920
- VWAP
- 235.03
- Vol
- 1.67M
- Mkt Cap
- 24.26B
- Low
- 233.510
- Amount
- 393.32M
- EV/EBITDA, TTM
- 12.68
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and others. It also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as owns a urology management services organization (MSO). Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. It connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
AI analysis of Cardinal Health, Inc. (CAH)
buyCardinal Health Inc is a good buy right now due to its strong projected earnings growth of 13-15% for fiscal 2027, with analysts targeting a price increase to between $260 and $280, compared to the current price of $234.55. Additionally, the stock has shown a year-to-date change of +14.01%, indicating positive momentum.
Analyst Ratings (16)
-4.02% downside
Hold
1 Buy
15 Hold
0 Sell
Current: 234.62
Tief
209.00
Durchschnitt
225.18
Hoch
244.00
RBC Capital
Outperform
$276
2026-08-19
RBC Capital
2026-08-19
Kursziel
$276
Outperform
TD Cowen
Buy
$280
2026-08-13
TD Cowen
2026-08-13
Kursziel
$280
Buy
JPMorgan
Neutral
$260
2026-08-13
JPMorgan
2026-08-13
Kursziel
$260
Neutral
Barclays
Overweight
$275
2026-08-13
Barclays
2026-08-13
Kursziel
$275
Overweight
Morgan Stanley
Overweight
$265
2026-08-12
Morgan Stanley
2026-08-12
Kursziel
$265
Overweight
Bewertungskennzahlen
The current forward P/E ratio for Cardinal Health, Inc. (CAH) is 18.69, compared to its 5-year average forward P/E of 14.07.
Alphio AI Price Scenarios for CAH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CAH
Event-Zeitleiste
News
6.508-29Yahoo FinanceComparing AbbVie and Johnson & Johnson for Investment
8.508-27NASDAQ.COMCatheter Precision Inc. Reports Growth in Product Lines
6.508-24CNBCJim Cramer Reduces Broadcom Stake, Increases Cardinal Health Investment
5.008-23FoolAnalysis of Cardinal Health Executive Stock Transaction
5.008-23NASDAQ.COMCardinal Health Executive Sells Shares Amid Strong Stock Performance
CAH FAQ — answered by Alphio AI
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and others. It also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as owns a urology management services organization (MSO). Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. It connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).
Cardinal Health Inc is a good buy right now due to its strong projected earnings growth of 13-15% for fiscal 2027, with analysts targeting a price increase to between $260 and $280, compared to the current price of $234.55. Additionally, the stock has shown a year-to-date change of +14.01%, indicating positive momentum.
16 analysts cover CAH: 1 rate it Buy, 15 Hold and 0 Sell. The average price target is 225.18.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.